Mayne Pharma Group Share Price and Company Fundamentals
Last traded: Yesterday at 6:10 AM
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, the United States, Asia, and internationally. The company operates through four segments: Generic Products, Specialty Products, Metrics Contract Services, and Mayne Pharma International. It provides oral drug delivery systems; and contract pharmaceutical development, manufacturing, and analytical services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
|Primary activities||Develops, manufactures and markets branded and generic pharmaceutical products globally|
|Industry / Sector||Drug Manufacturers—General / Healthcare|
|Mailing address||1538 Main North Road Salisbury South SA 5106 Australia|
|Phone / Fax||61 8 8209 2666 / 61 8 8281 0284|
|Share registry||COMPUTERSHARE INVESTOR SERVICES PTY LIMITED|
Mayne Pharma Group does not pay dividends.
As of Sep 2021, following are the company executives and directors listed on Mayne Pharma Group.
|Mr. Scott Anthony Richards||MD, CEO & Exec. Director||56||1.4M|
|Mr. Peter Paltoglou||Chief Financial Officer||651.38k|
|Mr. Stefan J. Cross||Pres of International Operations||47|
|Ms. Lisa Pendlebury||VP of Investor Relations & Communications|
|Ms. Kate Hall||Exec. VP & Gen. Counsel|
|Dr. Andrew O. Herdman Ph.D.||VP of Group HR|
|Mr. Brant Schofield||Exec. VP of Specialty Products Division||54|
|Mr. Daniel Moore||Exec. VP of Generics Products Division|
|Mr. Gerard G. Nahum M.D.||Chief Medical Officer|
|Mr. Donald Pearl||Exec. VP of Women's Health|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Mayne Pharma Group is 520.63M and its enterprise value is 773.77M. The enterprise value to revenue ratio of MYX is 1.93.
The MYX's stocks Beta value is 0.93 making it 7% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Mayne Pharma Group (MYX)
Mayne Pharma Group (ASX:MYX) Frequently Asked Questions
1. What is Mayne Pharma Group's Stock Symbol?
Mayne Pharma Group trades on ASX under the ticker symbol "MYX".
2. What is Mayne Pharma Group's stock price today?
One share of MYX stock can currently be purchased for approximately $0.295.
3. How can I contact Mayne Pharma Group?
Mayne Pharma Group's mailing address is 1538 Main North Road Salisbury South SA 5106 Australia. The company can be reached via phone at 61 8 8209 2666.
4. What is Mayne Pharma Group's official website?
The official website of Mayne Pharma Group is http://www.maynepharma.com.
5. Which share registry manages Mayne Pharma Group's stock?
Mayne Pharma Group's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.